Terrie Curran, Phathom Pharmaceuticals CEO
FDA decision, launch of gastrointestinal drug delayed after nitrosamine found in commercial batches
Takeda spinout Phathom Pharmaceuticals’ lead gastrointestinal drug has hit a snag with the FDA, the company announced Tuesday, and won’t hit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.